Lawsuit filed for Investors who lost money with shares of Semler Scientific, Inc. (NASDAQ: SMLR)

An investor, who purchased shares of Semler Scientific, Inc. (NASDAQ: SMLR), filed a lawsuit over alleged violations of Federal Securities Laws by Semler Scientific, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Semler Scientific, Inc. (NASDAQ: SMLR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 28, 2025. NASDAQ: SMLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Santa Clara, CA based Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. Semler Scientific, Inc. (NASDAQ: SMLR) reported that its annual Total Revenue declined from $68.18 million in 2023 to $56.29 million in 2024, and that its Net Income increased from $20.58 million in 2023 to $40.89 million in 2024.

On February 28, 2025, Semler Scientific, Inc. disclosed that "[i]n July 2017, the Company received an initial civil investigative demand ("CID") from the U.S. Department of Justice ("DOJ") pursuant to the federal False Claims Act investigating whether the Company and others may have violated the False Claims Act by marketing tests on devices that use photoplethysmography technology as reimbursable by Medicare in alleged contravention of applicable laws and regulations," and that "there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages."

Then, on April 15, 2025, Semler Scientific, Inc. revealed that it "reached agreement in principle on payment of $29.75 million to settle all claims (which amount excludes any potential relator counsel fees that may also be payable)".

Shares of Semler Scientific, Inc. (NASDAQ: SMLR) declined from $153.21 per share on October 29, 2021 to as low as $27.55 per share on September 04, 2025.

The plaintiff claims that between March 10, 2021 and April 15, 2025, the defendants made false and/or misleading statements and/or failed to disclose that Semler Scientific did not disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims (and aggressive DOJ enforcement thereof) in hypothetical terms, and that as a result, defendants public statements were materially false and/or misleading at all relevant times.

Those who purchased shares of Semler Scientific, Inc. (NASDAQ: SMLR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.